GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ADC Therapeutics SA (NYSE:ADCT) » Definitions » Research & Development

ADC Therapeutics (ADC Therapeutics) Research & Development : $113.38 Mil (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is ADC Therapeutics Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. ADC Therapeutics's Research & Development for the three months ended in Mar. 2024 was $25.74 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was $113.38 Mil.

ADC Therapeutics Research & Development Historical Data

The historical data trend for ADC Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ADC Therapeutics Research & Development Chart

ADC Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial 107.54 142.03 158.00 186.46 127.13

ADC Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.38 31.94 28.44 27.26 25.74

ADC Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $113.38 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ADC Therapeutics  (NYSE:ADCT) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

ADC Therapeutics Research & Development Related Terms

Thank you for viewing the detailed overview of ADC Therapeutics's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

ADC Therapeutics (ADC Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ADC Therapeutics SA (NYSE:ADCT) » Definitions » Research & Development
Comparable Companies
IOBT TSBX ACET HCWB ANEB XLO CLGN ATHA KZR ELTX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
Route de la Corniche 3B, Biopole, Epalinges, CHE, 1066
Website
https://www.adctherapeutics.com
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.